nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—MET—stomach cancer	0.311	1	CbGaD
Crizotinib—AURKA—Epirubicin—stomach cancer	0.164	0.551	CbGbCtD
Crizotinib—AURKA—Doxorubicin—stomach cancer	0.0872	0.293	CbGbCtD
Crizotinib—ABCB1—Mitomycin—stomach cancer	0.0169	0.0568	CbGbCtD
Crizotinib—CYP3A5—Irinotecan—stomach cancer	0.00666	0.0224	CbGbCtD
Crizotinib—CYP3A5—Docetaxel—stomach cancer	0.00488	0.0164	CbGbCtD
Crizotinib—ABCB1—Irinotecan—stomach cancer	0.00434	0.0146	CbGbCtD
Crizotinib—ABCB1—Docetaxel—stomach cancer	0.00318	0.0107	CbGbCtD
Crizotinib—CYP3A4—Irinotecan—stomach cancer	0.0026	0.00872	CbGbCtD
Crizotinib—ABCB1—Doxorubicin—stomach cancer	0.00237	0.00795	CbGbCtD
Crizotinib—ABCB1—Methotrexate—stomach cancer	0.00229	0.0077	CbGbCtD
Crizotinib—CYP3A4—Docetaxel—stomach cancer	0.0019	0.00639	CbGbCtD
Crizotinib—CYP3A4—Doxorubicin—stomach cancer	0.00142	0.00477	CbGbCtD
Crizotinib—IGF1R—Topotecan—Irinotecan—stomach cancer	0.000569	0.152	CbGdCrCtD
Crizotinib—CDK7—Topotecan—Irinotecan—stomach cancer	0.000459	0.123	CbGdCrCtD
Crizotinib—PLK4—Topotecan—Irinotecan—stomach cancer	0.000299	0.0798	CbGdCrCtD
Crizotinib—TYRO3—endocrine gland—stomach cancer	0.000283	0.00266	CbGeAlD
Crizotinib—YES1—hematopoietic system—stomach cancer	0.000282	0.00266	CbGeAlD
Crizotinib—LYN—endocrine gland—stomach cancer	0.000281	0.00265	CbGeAlD
Crizotinib—EPHB4—smooth muscle tissue—stomach cancer	0.000281	0.00265	CbGeAlD
Crizotinib—IRAK1—pancreas—stomach cancer	0.00028	0.00264	CbGeAlD
Crizotinib—TNK1—endocrine gland—stomach cancer	0.00028	0.00264	CbGeAlD
Crizotinib—STK10—hematopoietic system—stomach cancer	0.00028	0.00263	CbGeAlD
Crizotinib—TEK—epithelium—stomach cancer	0.00028	0.00263	CbGeAlD
Crizotinib—JAK2—smooth muscle tissue—stomach cancer	0.000279	0.00263	CbGeAlD
Crizotinib—TAOK3—hematopoietic system—stomach cancer	0.000279	0.00262	CbGeAlD
Crizotinib—MERTK—bone marrow—stomach cancer	0.000277	0.00261	CbGeAlD
Crizotinib—BMPR1B—endocrine gland—stomach cancer	0.000277	0.00261	CbGeAlD
Crizotinib—PRKD3—lymph node—stomach cancer	0.000276	0.0026	CbGeAlD
Crizotinib—RPS6KB1—pancreas—stomach cancer	0.000275	0.00259	CbGeAlD
Crizotinib—IGF1R—endocrine gland—stomach cancer	0.000272	0.00256	CbGeAlD
Crizotinib—TNK2—endocrine gland—stomach cancer	0.000272	0.00256	CbGeAlD
Crizotinib—SRC—hematopoietic system—stomach cancer	0.000272	0.00256	CbGeAlD
Crizotinib—NUAK2—bone marrow—stomach cancer	0.00027	0.00254	CbGeAlD
Crizotinib—STK4—liver—stomach cancer	0.00027	0.00254	CbGeAlD
Crizotinib—DSTYK—lymph node—stomach cancer	0.00027	0.00254	CbGeAlD
Crizotinib—TEK—smooth muscle tissue—stomach cancer	0.000269	0.00254	CbGeAlD
Crizotinib—MAP4K5—smooth muscle tissue—stomach cancer	0.000269	0.00254	CbGeAlD
Crizotinib—PTK2B—lymphoid tissue—stomach cancer	0.000268	0.00253	CbGeAlD
Crizotinib—FLT3—bone marrow—stomach cancer	0.000268	0.00253	CbGeAlD
Crizotinib—ACVR1—bone marrow—stomach cancer	0.000268	0.00253	CbGeAlD
Crizotinib—MAP4K2—endocrine gland—stomach cancer	0.000268	0.00252	CbGeAlD
Crizotinib—BLK—lymph node—stomach cancer	0.000267	0.00251	CbGeAlD
Crizotinib—PTK2B—digestive system—stomach cancer	0.000265	0.0025	CbGeAlD
Crizotinib—LTK—lymph node—stomach cancer	0.000264	0.00248	CbGeAlD
Crizotinib—CASK—lymph node—stomach cancer	0.000264	0.00248	CbGeAlD
Crizotinib—RIPK2—digestive system—stomach cancer	0.000263	0.00248	CbGeAlD
Crizotinib—SLK—pancreas—stomach cancer	0.000262	0.00247	CbGeAlD
Crizotinib—EPHB4—pancreas—stomach cancer	0.00026	0.00245	CbGeAlD
Crizotinib—AURKA—endocrine gland—stomach cancer	0.000258	0.00243	CbGeAlD
Crizotinib—TESK1—endocrine gland—stomach cancer	0.000256	0.00241	CbGeAlD
Crizotinib—MAPK7—lymph node—stomach cancer	0.000255	0.0024	CbGeAlD
Crizotinib—TXK—lymph node—stomach cancer	0.000255	0.0024	CbGeAlD
Crizotinib—EPHA2—pancreas—stomach cancer	0.000255	0.0024	CbGeAlD
Crizotinib—FER—liver—stomach cancer	0.000255	0.0024	CbGeAlD
Crizotinib—LYN—liver—stomach cancer	0.000254	0.00239	CbGeAlD
Crizotinib—BMP2K—bone marrow—stomach cancer	0.000253	0.00238	CbGeAlD
Crizotinib—FES—lymph node—stomach cancer	0.000253	0.00238	CbGeAlD
Crizotinib—TNK1—liver—stomach cancer	0.000252	0.00238	CbGeAlD
Crizotinib—MAP3K2—lymphoid tissue—stomach cancer	0.000252	0.00238	CbGeAlD
Crizotinib—ABL1—Topotecan—Irinotecan—stomach cancer	0.000251	0.0671	CbGdCrCtD
Crizotinib—TEK—pancreas—stomach cancer	0.000249	0.00234	CbGeAlD
Crizotinib—MAP4K5—pancreas—stomach cancer	0.000249	0.00234	CbGeAlD
Crizotinib—YES1—smooth muscle tissue—stomach cancer	0.000249	0.00234	CbGeAlD
Crizotinib—MERTK—endocrine gland—stomach cancer	0.000249	0.00234	CbGeAlD
Crizotinib—SRC—epithelium—stomach cancer	0.000248	0.00234	CbGeAlD
Crizotinib—PTK2—lymphoid tissue—stomach cancer	0.000247	0.00233	CbGeAlD
Crizotinib—TBK1—lymphoid tissue—stomach cancer	0.000247	0.00233	CbGeAlD
Crizotinib—TYK2—lymphoid tissue—stomach cancer	0.000246	0.00231	CbGeAlD
Crizotinib—TNK2—liver—stomach cancer	0.000245	0.00231	CbGeAlD
Crizotinib—IGF1R—liver—stomach cancer	0.000245	0.00231	CbGeAlD
Crizotinib—PTK2B—bone marrow—stomach cancer	0.000244	0.0023	CbGeAlD
Crizotinib—PTK2—digestive system—stomach cancer	0.000244	0.0023	CbGeAlD
Crizotinib—TBK1—digestive system—stomach cancer	0.000244	0.0023	CbGeAlD
Crizotinib—CSF1R—hematopoietic system—stomach cancer	0.000244	0.0023	CbGeAlD
Crizotinib—LIMK2—endocrine gland—stomach cancer	0.000243	0.00229	CbGeAlD
Crizotinib—TYK2—digestive system—stomach cancer	0.000243	0.00228	CbGeAlD
Crizotinib—RIPK2—bone marrow—stomach cancer	0.000242	0.00228	CbGeAlD
Crizotinib—MAP4K2—liver—stomach cancer	0.000242	0.00227	CbGeAlD
Crizotinib—MAP3K12—endocrine gland—stomach cancer	0.000241	0.00226	CbGeAlD
Crizotinib—FLT3—endocrine gland—stomach cancer	0.000241	0.00226	CbGeAlD
Crizotinib—ACVR1—endocrine gland—stomach cancer	0.000241	0.00226	CbGeAlD
Crizotinib—SRC—smooth muscle tissue—stomach cancer	0.000239	0.00225	CbGeAlD
Crizotinib—MET—lymph node—stomach cancer	0.000239	0.00225	CbGeAlD
Crizotinib—STK3—liver—stomach cancer	0.000238	0.00224	CbGeAlD
Crizotinib—TIE1—liver—stomach cancer	0.000238	0.00224	CbGeAlD
Crizotinib—RPS6KB1—lymphoid tissue—stomach cancer	0.000238	0.00224	CbGeAlD
Crizotinib—FGR—lymphoid tissue—stomach cancer	0.000236	0.00222	CbGeAlD
Crizotinib—STK35—endocrine gland—stomach cancer	0.000236	0.00222	CbGeAlD
Crizotinib—AXL—lymphoid tissue—stomach cancer	0.000235	0.00222	CbGeAlD
Crizotinib—RPS6KB1—digestive system—stomach cancer	0.000235	0.00221	CbGeAlD
Crizotinib—AURKA—Topotecan—Irinotecan—stomach cancer	0.000234	0.0625	CbGdCrCtD
Crizotinib—FGR—digestive system—stomach cancer	0.000233	0.0022	CbGeAlD
Crizotinib—AURKA—liver—stomach cancer	0.000232	0.00219	CbGeAlD
Crizotinib—CDK7—lymph node—stomach cancer	0.000231	0.00218	CbGeAlD
Crizotinib—TESK1—liver—stomach cancer	0.00023	0.00217	CbGeAlD
Crizotinib—YES1—pancreas—stomach cancer	0.00023	0.00216	CbGeAlD
Crizotinib—MAP3K2—bone marrow—stomach cancer	0.00023	0.00216	CbGeAlD
Crizotinib—TAOK2—lymph node—stomach cancer	0.000229	0.00216	CbGeAlD
Crizotinib—TAOK3—pancreas—stomach cancer	0.000227	0.00214	CbGeAlD
Crizotinib—BMP2K—endocrine gland—stomach cancer	0.000227	0.00214	CbGeAlD
Crizotinib—TBK1—bone marrow—stomach cancer	0.000225	0.00212	CbGeAlD
Crizotinib—MERTK—liver—stomach cancer	0.000224	0.00211	CbGeAlD
Crizotinib—TYK2—bone marrow—stomach cancer	0.000224	0.0021	CbGeAlD
Crizotinib—JAK2—lymphoid tissue—stomach cancer	0.000223	0.0021	CbGeAlD
Crizotinib—EPHB4—digestive system—stomach cancer	0.000222	0.00209	CbGeAlD
Crizotinib—SRC—pancreas—stomach cancer	0.000221	0.00208	CbGeAlD
Crizotinib—EPHA3—lymph node—stomach cancer	0.000221	0.00208	CbGeAlD
Crizotinib—ACVR1B—lymph node—stomach cancer	0.000221	0.00208	CbGeAlD
Crizotinib—EPHA2—lymphoid tissue—stomach cancer	0.000221	0.00208	CbGeAlD
Crizotinib—IRAK1—bone marrow—stomach cancer	0.000221	0.00208	CbGeAlD
Crizotinib—JAK2—digestive system—stomach cancer	0.000221	0.00208	CbGeAlD
Crizotinib—LIMK2—liver—stomach cancer	0.000219	0.00206	CbGeAlD
Crizotinib—PTK2B—endocrine gland—stomach cancer	0.000219	0.00206	CbGeAlD
Crizotinib—NUAK2—liver—stomach cancer	0.000218	0.00206	CbGeAlD
Crizotinib—EPHA2—digestive system—stomach cancer	0.000218	0.00205	CbGeAlD
Crizotinib—RIPK2—endocrine gland—stomach cancer	0.000217	0.00205	CbGeAlD
Crizotinib—MAP3K12—liver—stomach cancer	0.000217	0.00204	CbGeAlD
Crizotinib—FLT3—liver—stomach cancer	0.000217	0.00204	CbGeAlD
Crizotinib—ACVR1—liver—stomach cancer	0.000217	0.00204	CbGeAlD
Crizotinib—RPS6KB1—bone marrow—stomach cancer	0.000217	0.00204	CbGeAlD
Crizotinib—TEK—lymphoid tissue—stomach cancer	0.000215	0.00203	CbGeAlD
Crizotinib—MAP4K5—lymphoid tissue—stomach cancer	0.000215	0.00203	CbGeAlD
Crizotinib—FGR—bone marrow—stomach cancer	0.000215	0.00203	CbGeAlD
Crizotinib—LCK—bone marrow—stomach cancer	0.000215	0.00203	CbGeAlD
Crizotinib—CSF1R—smooth muscle tissue—stomach cancer	0.000215	0.00202	CbGeAlD
Crizotinib—STK35—liver—stomach cancer	0.000212	0.002	CbGeAlD
Crizotinib—JAK3—lymph node—stomach cancer	0.000211	0.00198	CbGeAlD
Crizotinib—EPHA4—endocrine gland—stomach cancer	0.00021	0.00198	CbGeAlD
Crizotinib—DCLK1—lymph node—stomach cancer	0.000209	0.00197	CbGeAlD
Crizotinib—PLK4—lymph node—stomach cancer	0.000208	0.00196	CbGeAlD
Crizotinib—ABL2—liver—stomach cancer	0.000207	0.00195	CbGeAlD
Crizotinib—STK4—lymph node—stomach cancer	0.000207	0.00195	CbGeAlD
Crizotinib—SLK—bone marrow—stomach cancer	0.000206	0.00194	CbGeAlD
Crizotinib—MAP3K2—endocrine gland—stomach cancer	0.000206	0.00194	CbGeAlD
Crizotinib—EPHB4—bone marrow—stomach cancer	0.000205	0.00193	CbGeAlD
Crizotinib—BMP2K—liver—stomach cancer	0.000205	0.00193	CbGeAlD
Crizotinib—JAK2—bone marrow—stomach cancer	0.000203	0.00191	CbGeAlD
Crizotinib—TBK1—endocrine gland—stomach cancer	0.000202	0.0019	CbGeAlD
Crizotinib—PTK2—endocrine gland—stomach cancer	0.000202	0.0019	CbGeAlD
Crizotinib—TYK2—endocrine gland—stomach cancer	0.0002	0.00189	CbGeAlD
Crizotinib—YES1—lymphoid tissue—stomach cancer	0.000199	0.00187	CbGeAlD
Crizotinib—PTK2B—liver—stomach cancer	0.000198	0.00186	CbGeAlD
Crizotinib—STK10—lymphoid tissue—stomach cancer	0.000197	0.00185	CbGeAlD
Crizotinib—YES1—digestive system—stomach cancer	0.000196	0.00185	CbGeAlD
Crizotinib—TAOK3—lymphoid tissue—stomach cancer	0.000196	0.00185	CbGeAlD
Crizotinib—MAP3K3—bone marrow—stomach cancer	0.000196	0.00185	CbGeAlD
Crizotinib—MAP4K5—bone marrow—stomach cancer	0.000196	0.00185	CbGeAlD
Crizotinib—RIPK2—liver—stomach cancer	0.000196	0.00184	CbGeAlD
Crizotinib—ALK—lymph node—stomach cancer	0.000196	0.00184	CbGeAlD
Crizotinib—FER—lymph node—stomach cancer	0.000196	0.00184	CbGeAlD
Crizotinib—STK10—digestive system—stomach cancer	0.000195	0.00183	CbGeAlD
Crizotinib—RPS6KB1—endocrine gland—stomach cancer	0.000194	0.00183	CbGeAlD
Crizotinib—TAOK3—digestive system—stomach cancer	0.000194	0.00182	CbGeAlD
Crizotinib—TNK1—lymph node—stomach cancer	0.000194	0.00182	CbGeAlD
Crizotinib—FGR—endocrine gland—stomach cancer	0.000193	0.00182	CbGeAlD
Crizotinib—ABL1—hematopoietic system—stomach cancer	0.000193	0.00181	CbGeAlD
Crizotinib—AXL—endocrine gland—stomach cancer	0.000192	0.00181	CbGeAlD
Crizotinib—BMPR1B—lymph node—stomach cancer	0.000192	0.0018	CbGeAlD
Crizotinib—MAP4K1—lymph node—stomach cancer	0.000192	0.0018	CbGeAlD
Crizotinib—SRC—lymphoid tissue—stomach cancer	0.000191	0.0018	CbGeAlD
Crizotinib—SRC—digestive system—stomach cancer	0.000189	0.00178	CbGeAlD
Crizotinib—TNK2—lymph node—stomach cancer	0.000188	0.00177	CbGeAlD
Crizotinib—IGF1R—lymph node—stomach cancer	0.000188	0.00177	CbGeAlD
Crizotinib—MAP3K2—liver—stomach cancer	0.000186	0.00175	CbGeAlD
Crizotinib—MAP4K2—lymph node—stomach cancer	0.000185	0.00174	CbGeAlD
Crizotinib—EPHB4—endocrine gland—stomach cancer	0.000184	0.00173	CbGeAlD
Crizotinib—TIE1—lymph node—stomach cancer	0.000183	0.00172	CbGeAlD
Crizotinib—STK3—lymph node—stomach cancer	0.000183	0.00172	CbGeAlD
Crizotinib—JAK2—endocrine gland—stomach cancer	0.000182	0.00172	CbGeAlD
Crizotinib—TBK1—liver—stomach cancer	0.000182	0.00171	CbGeAlD
Crizotinib—PTK2—liver—stomach cancer	0.000182	0.00171	CbGeAlD
Crizotinib—YES1—bone marrow—stomach cancer	0.000181	0.0017	CbGeAlD
Crizotinib—TYK2—liver—stomach cancer	0.000181	0.0017	CbGeAlD
Crizotinib—EPHA2—endocrine gland—stomach cancer	0.00018	0.0017	CbGeAlD
Crizotinib—STK10—bone marrow—stomach cancer	0.000179	0.00169	CbGeAlD
Crizotinib—TAOK3—bone marrow—stomach cancer	0.000179	0.00168	CbGeAlD
Crizotinib—IRAK1—liver—stomach cancer	0.000178	0.00168	CbGeAlD
Crizotinib—AURKA—lymph node—stomach cancer	0.000178	0.00168	CbGeAlD
Crizotinib—TESK1—lymph node—stomach cancer	0.000177	0.00166	CbGeAlD
Crizotinib—MAP4K5—endocrine gland—stomach cancer	0.000176	0.00165	CbGeAlD
Crizotinib—TEK—endocrine gland—stomach cancer	0.000176	0.00165	CbGeAlD
Crizotinib—MAP3K3—endocrine gland—stomach cancer	0.000176	0.00165	CbGeAlD
Crizotinib—RPS6KB1—liver—stomach cancer	0.000175	0.00165	CbGeAlD
Crizotinib—LCK—liver—stomach cancer	0.000174	0.00164	CbGeAlD
Crizotinib—FGR—liver—stomach cancer	0.000174	0.00164	CbGeAlD
Crizotinib—AXL—liver—stomach cancer	0.000173	0.00163	CbGeAlD
Crizotinib—MERTK—lymph node—stomach cancer	0.000172	0.00162	CbGeAlD
Crizotinib—CSF1R—lymphoid tissue—stomach cancer	0.000172	0.00162	CbGeAlD
Crizotinib—ABL1—smooth muscle tissue—stomach cancer	0.00017	0.0016	CbGeAlD
Crizotinib—CSF1R—digestive system—stomach cancer	0.00017	0.0016	CbGeAlD
Crizotinib—LIMK2—lymph node—stomach cancer	0.000168	0.00158	CbGeAlD
Crizotinib—NUAK2—lymph node—stomach cancer	0.000167	0.00158	CbGeAlD
Crizotinib—SLK—liver—stomach cancer	0.000167	0.00157	CbGeAlD
Crizotinib—ACVR1—lymph node—stomach cancer	0.000166	0.00157	CbGeAlD
Crizotinib—MAP3K12—lymph node—stomach cancer	0.000166	0.00157	CbGeAlD
Crizotinib—FLT3—lymph node—stomach cancer	0.000166	0.00157	CbGeAlD
Crizotinib—EPHB4—liver—stomach cancer	0.000166	0.00156	CbGeAlD
Crizotinib—JAK2—liver—stomach cancer	0.000164	0.00155	CbGeAlD
Crizotinib—STK35—lymph node—stomach cancer	0.000163	0.00153	CbGeAlD
Crizotinib—EPHA2—liver—stomach cancer	0.000162	0.00153	CbGeAlD
Crizotinib—YES1—endocrine gland—stomach cancer	0.000162	0.00153	CbGeAlD
Crizotinib—STK10—endocrine gland—stomach cancer	0.000161	0.00151	CbGeAlD
Crizotinib—TAOK3—endocrine gland—stomach cancer	0.00016	0.00151	CbGeAlD
Crizotinib—ABL2—lymph node—stomach cancer	0.000159	0.00149	CbGeAlD
Crizotinib—MAP4K5—liver—stomach cancer	0.000158	0.00149	CbGeAlD
Crizotinib—TEK—liver—stomach cancer	0.000158	0.00149	CbGeAlD
Crizotinib—MAP3K3—liver—stomach cancer	0.000158	0.00149	CbGeAlD
Crizotinib—ABL1—pancreas—stomach cancer	0.000157	0.00148	CbGeAlD
Crizotinib—BMP2K—lymph node—stomach cancer	0.000157	0.00148	CbGeAlD
Crizotinib—Hepatic function abnormal—Doxorubicin—stomach cancer	0.000156	0.00165	CcSEcCtD
Crizotinib—CSF1R—bone marrow—stomach cancer	0.000156	0.00147	CbGeAlD
Crizotinib—SRC—endocrine gland—stomach cancer	0.000156	0.00147	CbGeAlD
Crizotinib—Oedema—Irinotecan—stomach cancer	0.000156	0.00164	CcSEcCtD
Crizotinib—Infection—Irinotecan—stomach cancer	0.000155	0.00163	CcSEcCtD
Crizotinib—Hepatobiliary disease—Capecitabine—stomach cancer	0.000155	0.00163	CcSEcCtD
Crizotinib—Shock—Irinotecan—stomach cancer	0.000153	0.00162	CcSEcCtD
Crizotinib—Nervous system disorder—Irinotecan—stomach cancer	0.000153	0.00161	CcSEcCtD
Crizotinib—Hepatic failure—Doxorubicin—stomach cancer	0.000152	0.0016	CcSEcCtD
Crizotinib—PTK2B—lymph node—stomach cancer	0.000151	0.00143	CbGeAlD
Crizotinib—Hypoaesthesia—Docetaxel—stomach cancer	0.000151	0.00159	CcSEcCtD
Crizotinib—RIPK2—lymph node—stomach cancer	0.00015	0.00141	CbGeAlD
Crizotinib—Urinary tract disorder—Docetaxel—stomach cancer	0.00015	0.00158	CcSEcCtD
Crizotinib—Bradycardia—Capecitabine—stomach cancer	0.000149	0.00157	CcSEcCtD
Crizotinib—Oedema peripheral—Docetaxel—stomach cancer	0.000149	0.00157	CcSEcCtD
Crizotinib—Oedema—Fluorouracil—stomach cancer	0.000149	0.00157	CcSEcCtD
Crizotinib—Urethral disorder—Docetaxel—stomach cancer	0.000149	0.00157	CcSEcCtD
Crizotinib—Infection—Fluorouracil—stomach cancer	0.000148	0.00156	CcSEcCtD
Crizotinib—Diplopia—Epirubicin—stomach cancer	0.000148	0.00156	CcSEcCtD
Crizotinib—YES1—liver—stomach cancer	0.000146	0.00138	CbGeAlD
Crizotinib—Nervous system disorder—Fluorouracil—stomach cancer	0.000146	0.00154	CcSEcCtD
Crizotinib—Visual impairment—Docetaxel—stomach cancer	0.000146	0.00154	CcSEcCtD
Crizotinib—Hypoaesthesia—Capecitabine—stomach cancer	0.000146	0.00154	CcSEcCtD
Crizotinib—EPHA4—lymph node—stomach cancer	0.000145	0.00137	CbGeAlD
Crizotinib—STK10—liver—stomach cancer	0.000145	0.00136	CbGeAlD
Crizotinib—Urinary tract disorder—Capecitabine—stomach cancer	0.000145	0.00153	CcSEcCtD
Crizotinib—Oedema peripheral—Capecitabine—stomach cancer	0.000145	0.00152	CcSEcCtD
Crizotinib—TAOK3—liver—stomach cancer	0.000144	0.00136	CbGeAlD
Crizotinib—Urethral disorder—Capecitabine—stomach cancer	0.000144	0.00152	CcSEcCtD
Crizotinib—Face oedema—Epirubicin—stomach cancer	0.000143	0.0015	CcSEcCtD
Crizotinib—MAP3K2—lymph node—stomach cancer	0.000142	0.00134	CbGeAlD
Crizotinib—Eye disorder—Docetaxel—stomach cancer	0.000142	0.00149	CcSEcCtD
Crizotinib—Visual impairment—Capecitabine—stomach cancer	0.000141	0.00149	CcSEcCtD
Crizotinib—SRC—liver—stomach cancer	0.000141	0.00132	CbGeAlD
Crizotinib—Cardiac disorder—Docetaxel—stomach cancer	0.000141	0.00148	CcSEcCtD
Crizotinib—CSF1R—endocrine gland—stomach cancer	0.00014	0.00132	CbGeAlD
Crizotinib—Paraesthesia—Irinotecan—stomach cancer	0.00014	0.00147	CcSEcCtD
Crizotinib—PTK2—lymph node—stomach cancer	0.000139	0.00131	CbGeAlD
Crizotinib—TBK1—lymph node—stomach cancer	0.000139	0.00131	CbGeAlD
Crizotinib—Dyspnoea—Irinotecan—stomach cancer	0.000139	0.00146	CcSEcCtD
Crizotinib—TYK2—lymph node—stomach cancer	0.000139	0.0013	CbGeAlD
Crizotinib—Eye disorder—Capecitabine—stomach cancer	0.000137	0.00145	CcSEcCtD
Crizotinib—Dyspepsia—Irinotecan—stomach cancer	0.000137	0.00145	CcSEcCtD
Crizotinib—IRAK1—lymph node—stomach cancer	0.000137	0.00129	CbGeAlD
Crizotinib—Diplopia—Doxorubicin—stomach cancer	0.000137	0.00144	CcSEcCtD
Crizotinib—Mediastinal disorder—Docetaxel—stomach cancer	0.000137	0.00144	CcSEcCtD
Crizotinib—Cardiac disorder—Capecitabine—stomach cancer	0.000136	0.00144	CcSEcCtD
Crizotinib—ABL1—lymphoid tissue—stomach cancer	0.000136	0.00128	CbGeAlD
Crizotinib—Decreased appetite—Irinotecan—stomach cancer	0.000135	0.00143	CcSEcCtD
Crizotinib—Arrhythmia—Docetaxel—stomach cancer	0.000135	0.00143	CcSEcCtD
Crizotinib—Hypokalaemia—Epirubicin—stomach cancer	0.000134	0.00142	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Irinotecan—stomach cancer	0.000134	0.00142	CcSEcCtD
Crizotinib—Fatigue—Irinotecan—stomach cancer	0.000134	0.00142	CcSEcCtD
Crizotinib—RPS6KB1—lymph node—stomach cancer	0.000134	0.00126	CbGeAlD
Crizotinib—ABL1—digestive system—stomach cancer	0.000134	0.00126	CbGeAlD
Crizotinib—Paraesthesia—Fluorouracil—stomach cancer	0.000134	0.00141	CcSEcCtD
Crizotinib—IGF1R—Idarubicin—Epirubicin—stomach cancer	0.000134	0.0357	CbGdCrCtD
Crizotinib—FGR—lymph node—stomach cancer	0.000133	0.00126	CbGeAlD
Crizotinib—LCK—lymph node—stomach cancer	0.000133	0.00126	CbGeAlD
Crizotinib—Constipation—Irinotecan—stomach cancer	0.000133	0.0014	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Epirubicin—stomach cancer	0.000133	0.0014	CcSEcCtD
Crizotinib—Dyspnoea—Fluorouracil—stomach cancer	0.000133	0.0014	CcSEcCtD
Crizotinib—AXL—lymph node—stomach cancer	0.000133	0.00125	CbGeAlD
Crizotinib—Mediastinal disorder—Capecitabine—stomach cancer	0.000132	0.00139	CcSEcCtD
Crizotinib—Face oedema—Doxorubicin—stomach cancer	0.000132	0.00139	CcSEcCtD
Crizotinib—Malnutrition—Docetaxel—stomach cancer	0.000132	0.00139	CcSEcCtD
Crizotinib—Dyspepsia—Fluorouracil—stomach cancer	0.000131	0.00138	CcSEcCtD
Crizotinib—Arrhythmia—Capecitabine—stomach cancer	0.000131	0.00138	CcSEcCtD
Crizotinib—Muscular weakness—Epirubicin—stomach cancer	0.00013	0.00137	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Epirubicin—stomach cancer	0.00013	0.00137	CcSEcCtD
Crizotinib—Decreased appetite—Fluorouracil—stomach cancer	0.00013	0.00137	CcSEcCtD
Crizotinib—Dysgeusia—Docetaxel—stomach cancer	0.000129	0.00136	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Fluorouracil—stomach cancer	0.000129	0.00136	CcSEcCtD
Crizotinib—SLK—lymph node—stomach cancer	0.000128	0.0012	CbGeAlD
Crizotinib—Malnutrition—Capecitabine—stomach cancer	0.000128	0.00135	CcSEcCtD
Crizotinib—Neutropenia—Methotrexate—stomach cancer	0.000128	0.00134	CcSEcCtD
Crizotinib—EPHB4—lymph node—stomach cancer	0.000127	0.00119	CbGeAlD
Crizotinib—Upper respiratory tract infection—Methotrexate—stomach cancer	0.000127	0.00134	CcSEcCtD
Crizotinib—CSF1R—liver—stomach cancer	0.000126	0.00119	CbGeAlD
Crizotinib—JAK2—lymph node—stomach cancer	0.000126	0.00119	CbGeAlD
Crizotinib—Dysgeusia—Capecitabine—stomach cancer	0.000125	0.00132	CcSEcCtD
Crizotinib—EPHA2—lymph node—stomach cancer	0.000125	0.00117	CbGeAlD
Crizotinib—Hypokalaemia—Doxorubicin—stomach cancer	0.000124	0.00131	CcSEcCtD
Crizotinib—IGF1R—Idarubicin—Doxorubicin—stomach cancer	0.000124	0.0331	CbGdCrCtD
Crizotinib—ABL1—bone marrow—stomach cancer	0.000124	0.00116	CbGeAlD
Crizotinib—Body temperature increased—Irinotecan—stomach cancer	0.000123	0.0013	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Doxorubicin—stomach cancer	0.000123	0.0013	CcSEcCtD
Crizotinib—Pneumonia—Methotrexate—stomach cancer	0.000122	0.00129	CcSEcCtD
Crizotinib—AURKA—Cladribine—Floxuridine—stomach cancer	0.000122	0.0326	CbGdCrCtD
Crizotinib—Anaemia—Docetaxel—stomach cancer	0.000122	0.00129	CcSEcCtD
Crizotinib—Infestation NOS—Methotrexate—stomach cancer	0.000122	0.00128	CcSEcCtD
Crizotinib—Infestation—Methotrexate—stomach cancer	0.000122	0.00128	CcSEcCtD
Crizotinib—MAP3K3—lymph node—stomach cancer	0.000121	0.00114	CbGeAlD
Crizotinib—TEK—lymph node—stomach cancer	0.000121	0.00114	CbGeAlD
Crizotinib—MAP4K5—lymph node—stomach cancer	0.000121	0.00114	CbGeAlD
Crizotinib—Alanine aminotransferase increased—Doxorubicin—stomach cancer	0.000121	0.00127	CcSEcCtD
Crizotinib—Muscular weakness—Doxorubicin—stomach cancer	0.000121	0.00127	CcSEcCtD
Crizotinib—Vision blurred—Capecitabine—stomach cancer	0.00012	0.00127	CcSEcCtD
Crizotinib—Neutropenia—Epirubicin—stomach cancer	0.000119	0.00126	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Epirubicin—stomach cancer	0.000119	0.00125	CcSEcCtD
Crizotinib—Syncope—Docetaxel—stomach cancer	0.000118	0.00125	CcSEcCtD
Crizotinib—Leukopenia—Docetaxel—stomach cancer	0.000118	0.00124	CcSEcCtD
Crizotinib—Anaemia—Capecitabine—stomach cancer	0.000118	0.00124	CcSEcCtD
Crizotinib—Body temperature increased—Fluorouracil—stomach cancer	0.000118	0.00124	CcSEcCtD
Crizotinib—EPHB6—lymph node—stomach cancer	0.000116	0.00109	CbGeAlD
Crizotinib—Loss of consciousness—Docetaxel—stomach cancer	0.000116	0.00122	CcSEcCtD
Crizotinib—Weight decreased—Epirubicin—stomach cancer	0.000116	0.00122	CcSEcCtD
Crizotinib—Hepatobiliary disease—Methotrexate—stomach cancer	0.000115	0.00121	CcSEcCtD
Crizotinib—Syncope—Capecitabine—stomach cancer	0.000115	0.00121	CcSEcCtD
Crizotinib—Pneumonia—Epirubicin—stomach cancer	0.000114	0.00121	CcSEcCtD
Crizotinib—Leukopenia—Capecitabine—stomach cancer	0.000114	0.00121	CcSEcCtD
Crizotinib—Infestation—Epirubicin—stomach cancer	0.000114	0.0012	CcSEcCtD
Crizotinib—Infestation NOS—Epirubicin—stomach cancer	0.000114	0.0012	CcSEcCtD
Crizotinib—CYP3A5—hematopoietic system—stomach cancer	0.000113	0.00106	CbGeAlD
Crizotinib—ABCB1—blood vessel—stomach cancer	0.000113	0.00106	CbGeAlD
Crizotinib—Loss of consciousness—Capecitabine—stomach cancer	0.000112	0.00118	CcSEcCtD
Crizotinib—YES1—lymph node—stomach cancer	0.000112	0.00106	CbGeAlD
Crizotinib—Asthenia—Irinotecan—stomach cancer	0.000112	0.00118	CcSEcCtD
Crizotinib—Neuropathy peripheral—Epirubicin—stomach cancer	0.000112	0.00118	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—stomach cancer	0.000112	0.00118	CcSEcCtD
Crizotinib—STK10—lymph node—stomach cancer	0.000111	0.00105	CbGeAlD
Crizotinib—ABL1—endocrine gland—stomach cancer	0.000111	0.00104	CbGeAlD
Crizotinib—TAOK3—lymph node—stomach cancer	0.000111	0.00104	CbGeAlD
Crizotinib—Neutropenia—Doxorubicin—stomach cancer	0.00011	0.00116	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Doxorubicin—stomach cancer	0.00011	0.00116	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—stomach cancer	0.000108	0.00114	CcSEcCtD
Crizotinib—SRC—lymph node—stomach cancer	0.000108	0.00102	CbGeAlD
Crizotinib—Urinary tract disorder—Methotrexate—stomach cancer	0.000108	0.00114	CcSEcCtD
Crizotinib—CDK7—Doxorubicin—Epirubicin—stomach cancer	0.000108	0.0288	CbGdCrCtD
Crizotinib—CDK7—Daunorubicin—Epirubicin—stomach cancer	0.000108	0.0288	CbGdCrCtD
Crizotinib—CDK7—Idarubicin—Epirubicin—stomach cancer	0.000108	0.0288	CbGdCrCtD
Crizotinib—Hepatobiliary disease—Epirubicin—stomach cancer	0.000108	0.00114	CcSEcCtD
Crizotinib—Oedema—Docetaxel—stomach cancer	0.000108	0.00113	CcSEcCtD
Crizotinib—Urethral disorder—Methotrexate—stomach cancer	0.000107	0.00113	CcSEcCtD
Crizotinib—Infection—Docetaxel—stomach cancer	0.000107	0.00113	CcSEcCtD
Crizotinib—Weight decreased—Doxorubicin—stomach cancer	0.000107	0.00113	CcSEcCtD
Crizotinib—Diarrhoea—Irinotecan—stomach cancer	0.000107	0.00112	CcSEcCtD
Crizotinib—Pneumonia—Doxorubicin—stomach cancer	0.000106	0.00112	CcSEcCtD
Crizotinib—Shock—Docetaxel—stomach cancer	0.000106	0.00112	CcSEcCtD
Crizotinib—Nervous system disorder—Docetaxel—stomach cancer	0.000106	0.00111	CcSEcCtD
Crizotinib—Infestation NOS—Doxorubicin—stomach cancer	0.000105	0.00111	CcSEcCtD
Crizotinib—Infestation—Doxorubicin—stomach cancer	0.000105	0.00111	CcSEcCtD
Crizotinib—Visual impairment—Methotrexate—stomach cancer	0.000105	0.00111	CcSEcCtD
Crizotinib—Skin disorder—Docetaxel—stomach cancer	0.000105	0.0011	CcSEcCtD
Crizotinib—Oedema—Capecitabine—stomach cancer	0.000104	0.0011	CcSEcCtD
Crizotinib—Bradycardia—Epirubicin—stomach cancer	0.000104	0.0011	CcSEcCtD
Crizotinib—Infection—Capecitabine—stomach cancer	0.000104	0.00109	CcSEcCtD
Crizotinib—Neuropathy peripheral—Doxorubicin—stomach cancer	0.000103	0.00109	CcSEcCtD
Crizotinib—Dizziness—Irinotecan—stomach cancer	0.000103	0.00109	CcSEcCtD
Crizotinib—Shock—Capecitabine—stomach cancer	0.000103	0.00108	CcSEcCtD
Crizotinib—Nervous system disorder—Capecitabine—stomach cancer	0.000102	0.00108	CcSEcCtD
Crizotinib—Eye disorder—Methotrexate—stomach cancer	0.000102	0.00108	CcSEcCtD
Crizotinib—Diarrhoea—Fluorouracil—stomach cancer	0.000102	0.00108	CcSEcCtD
Crizotinib—Hypoaesthesia—Epirubicin—stomach cancer	0.000102	0.00107	CcSEcCtD
Crizotinib—Cardiac disorder—Methotrexate—stomach cancer	0.000101	0.00107	CcSEcCtD
Crizotinib—Skin disorder—Capecitabine—stomach cancer	0.000101	0.00107	CcSEcCtD
Crizotinib—Urinary tract disorder—Epirubicin—stomach cancer	0.000101	0.00106	CcSEcCtD
Crizotinib—Oedema peripheral—Epirubicin—stomach cancer	0.000101	0.00106	CcSEcCtD
Crizotinib—Urethral disorder—Epirubicin—stomach cancer	0.0001	0.00106	CcSEcCtD
Crizotinib—ABL1—liver—stomach cancer	9.99e-05	0.00094	CbGeAlD
Crizotinib—CDK7—Daunorubicin—Doxorubicin—stomach cancer	9.98e-05	0.0266	CbGdCrCtD
Crizotinib—CDK7—Epirubicin—Doxorubicin—stomach cancer	9.98e-05	0.0266	CbGdCrCtD
Crizotinib—CDK7—Idarubicin—Doxorubicin—stomach cancer	9.98e-05	0.0266	CbGdCrCtD
Crizotinib—Hepatobiliary disease—Doxorubicin—stomach cancer	9.96e-05	0.00105	CcSEcCtD
Crizotinib—Vomiting—Irinotecan—stomach cancer	9.9e-05	0.00104	CcSEcCtD
Crizotinib—Dizziness—Fluorouracil—stomach cancer	9.86e-05	0.00104	CcSEcCtD
Crizotinib—Visual impairment—Epirubicin—stomach cancer	9.85e-05	0.00104	CcSEcCtD
Crizotinib—Mediastinal disorder—Methotrexate—stomach cancer	9.84e-05	0.00104	CcSEcCtD
Crizotinib—Rash—Irinotecan—stomach cancer	9.82e-05	0.00104	CcSEcCtD
Crizotinib—Dermatitis—Irinotecan—stomach cancer	9.81e-05	0.00103	CcSEcCtD
Crizotinib—CSF1R—lymph node—stomach cancer	9.69e-05	0.000912	CbGeAlD
Crizotinib—Paraesthesia—Docetaxel—stomach cancer	9.67e-05	0.00102	CcSEcCtD
Crizotinib—Bradycardia—Doxorubicin—stomach cancer	9.63e-05	0.00101	CcSEcCtD
Crizotinib—Dyspnoea—Docetaxel—stomach cancer	9.6e-05	0.00101	CcSEcCtD
Crizotinib—Eye disorder—Epirubicin—stomach cancer	9.55e-05	0.00101	CcSEcCtD
Crizotinib—Malnutrition—Methotrexate—stomach cancer	9.51e-05	0.001	CcSEcCtD
Crizotinib—Cardiac disorder—Epirubicin—stomach cancer	9.48e-05	0.001	CcSEcCtD
Crizotinib—Vomiting—Fluorouracil—stomach cancer	9.48e-05	0.001	CcSEcCtD
Crizotinib—Dyspepsia—Docetaxel—stomach cancer	9.47e-05	0.000999	CcSEcCtD
Crizotinib—Hypoaesthesia—Doxorubicin—stomach cancer	9.41e-05	0.000992	CcSEcCtD
Crizotinib—Rash—Fluorouracil—stomach cancer	9.4e-05	0.000991	CcSEcCtD
Crizotinib—Dermatitis—Fluorouracil—stomach cancer	9.39e-05	0.00099	CcSEcCtD
Crizotinib—Paraesthesia—Capecitabine—stomach cancer	9.36e-05	0.000987	CcSEcCtD
Crizotinib—Decreased appetite—Docetaxel—stomach cancer	9.36e-05	0.000986	CcSEcCtD
Crizotinib—Urinary tract disorder—Doxorubicin—stomach cancer	9.34e-05	0.000984	CcSEcCtD
Crizotinib—Oedema peripheral—Doxorubicin—stomach cancer	9.31e-05	0.000982	CcSEcCtD
Crizotinib—Dysgeusia—Methotrexate—stomach cancer	9.31e-05	0.000981	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Docetaxel—stomach cancer	9.29e-05	0.00098	CcSEcCtD
Crizotinib—Dyspnoea—Capecitabine—stomach cancer	9.29e-05	0.00098	CcSEcCtD
Crizotinib—Fatigue—Docetaxel—stomach cancer	9.28e-05	0.000978	CcSEcCtD
Crizotinib—Urethral disorder—Doxorubicin—stomach cancer	9.27e-05	0.000977	CcSEcCtD
Crizotinib—Nausea—Irinotecan—stomach cancer	9.25e-05	0.000975	CcSEcCtD
Crizotinib—Mediastinal disorder—Epirubicin—stomach cancer	9.21e-05	0.000971	CcSEcCtD
Crizotinib—Constipation—Docetaxel—stomach cancer	9.2e-05	0.00097	CcSEcCtD
Crizotinib—CYP3A5—pancreas—stomach cancer	9.19e-05	0.000865	CbGeAlD
Crizotinib—Dyspepsia—Capecitabine—stomach cancer	9.17e-05	0.000967	CcSEcCtD
Crizotinib—Arrhythmia—Epirubicin—stomach cancer	9.13e-05	0.000962	CcSEcCtD
Crizotinib—Visual impairment—Doxorubicin—stomach cancer	9.11e-05	0.000961	CcSEcCtD
Crizotinib—Decreased appetite—Capecitabine—stomach cancer	9.06e-05	0.000955	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Capecitabine—stomach cancer	9e-05	0.000949	CcSEcCtD
Crizotinib—Fatigue—Capecitabine—stomach cancer	8.98e-05	0.000947	CcSEcCtD
Crizotinib—Vision blurred—Methotrexate—stomach cancer	8.96e-05	0.000944	CcSEcCtD
Crizotinib—Constipation—Capecitabine—stomach cancer	8.91e-05	0.00094	CcSEcCtD
Crizotinib—Malnutrition—Epirubicin—stomach cancer	8.9e-05	0.000938	CcSEcCtD
Crizotinib—Nausea—Fluorouracil—stomach cancer	8.86e-05	0.000934	CcSEcCtD
Crizotinib—Eye disorder—Doxorubicin—stomach cancer	8.84e-05	0.000932	CcSEcCtD
Crizotinib—Anaemia—Methotrexate—stomach cancer	8.79e-05	0.000926	CcSEcCtD
Crizotinib—Cardiac disorder—Doxorubicin—stomach cancer	8.78e-05	0.000925	CcSEcCtD
Crizotinib—Dysgeusia—Epirubicin—stomach cancer	8.71e-05	0.000918	CcSEcCtD
Crizotinib—Mediastinal disorder—Doxorubicin—stomach cancer	8.52e-05	0.000898	CcSEcCtD
Crizotinib—Body temperature increased—Docetaxel—stomach cancer	8.51e-05	0.000897	CcSEcCtD
Crizotinib—Leukopenia—Methotrexate—stomach cancer	8.51e-05	0.000897	CcSEcCtD
Crizotinib—CYP3A4—hematopoietic system—stomach cancer	8.47e-05	0.000797	CbGeAlD
Crizotinib—Arrhythmia—Doxorubicin—stomach cancer	8.45e-05	0.000891	CcSEcCtD
Crizotinib—Vision blurred—Epirubicin—stomach cancer	8.38e-05	0.000884	CcSEcCtD
Crizotinib—Body temperature increased—Capecitabine—stomach cancer	8.24e-05	0.000869	CcSEcCtD
Crizotinib—Malnutrition—Doxorubicin—stomach cancer	8.23e-05	0.000868	CcSEcCtD
Crizotinib—Anaemia—Epirubicin—stomach cancer	8.22e-05	0.000867	CcSEcCtD
Crizotinib—Dysgeusia—Doxorubicin—stomach cancer	8.06e-05	0.00085	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	8.04e-05	0.000847	CcSEcCtD
Crizotinib—Syncope—Epirubicin—stomach cancer	7.98e-05	0.000841	CcSEcCtD
Crizotinib—Leukopenia—Epirubicin—stomach cancer	7.96e-05	0.000839	CcSEcCtD
Crizotinib—CYP3A5—digestive system—stomach cancer	7.85e-05	0.000739	CbGeAlD
Crizotinib—Loss of consciousness—Epirubicin—stomach cancer	7.82e-05	0.000824	CcSEcCtD
Crizotinib—Vision blurred—Doxorubicin—stomach cancer	7.76e-05	0.000818	CcSEcCtD
Crizotinib—Asthenia—Docetaxel—stomach cancer	7.72e-05	0.000814	CcSEcCtD
Crizotinib—Infection—Methotrexate—stomach cancer	7.71e-05	0.000813	CcSEcCtD
Crizotinib—ABL1—lymph node—stomach cancer	7.66e-05	0.000721	CbGeAlD
Crizotinib—Nervous system disorder—Methotrexate—stomach cancer	7.61e-05	0.000802	CcSEcCtD
Crizotinib—Anaemia—Doxorubicin—stomach cancer	7.61e-05	0.000802	CcSEcCtD
Crizotinib—Skin disorder—Methotrexate—stomach cancer	7.54e-05	0.000794	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	7.52e-05	0.000793	CcSEcCtD
Crizotinib—Asthenia—Capecitabine—stomach cancer	7.48e-05	0.000788	CcSEcCtD
Crizotinib—Syncope—Doxorubicin—stomach cancer	7.38e-05	0.000778	CcSEcCtD
Crizotinib—Leukopenia—Doxorubicin—stomach cancer	7.37e-05	0.000777	CcSEcCtD
Crizotinib—Diarrhoea—Docetaxel—stomach cancer	7.36e-05	0.000776	CcSEcCtD
Crizotinib—Oedema—Epirubicin—stomach cancer	7.26e-05	0.000765	CcSEcCtD
Crizotinib—Loss of consciousness—Doxorubicin—stomach cancer	7.23e-05	0.000763	CcSEcCtD
Crizotinib—Infection—Epirubicin—stomach cancer	7.21e-05	0.00076	CcSEcCtD
Crizotinib—Shock—Epirubicin—stomach cancer	7.14e-05	0.000753	CcSEcCtD
Crizotinib—Diarrhoea—Capecitabine—stomach cancer	7.13e-05	0.000752	CcSEcCtD
Crizotinib—Nervous system disorder—Epirubicin—stomach cancer	7.12e-05	0.000751	CcSEcCtD
Crizotinib—Dizziness—Docetaxel—stomach cancer	7.12e-05	0.00075	CcSEcCtD
Crizotinib—Skin disorder—Epirubicin—stomach cancer	7.05e-05	0.000743	CcSEcCtD
Crizotinib—PLK4—Doxorubicin—Epirubicin—stomach cancer	7.03e-05	0.0188	CbGdCrCtD
Crizotinib—PLK4—Idarubicin—Epirubicin—stomach cancer	7.03e-05	0.0188	CbGdCrCtD
Crizotinib—Paraesthesia—Methotrexate—stomach cancer	6.97e-05	0.000734	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	6.96e-05	0.000734	CcSEcCtD
Crizotinib—Dyspnoea—Methotrexate—stomach cancer	6.92e-05	0.000729	CcSEcCtD
Crizotinib—Dizziness—Capecitabine—stomach cancer	6.89e-05	0.000727	CcSEcCtD
Crizotinib—Vomiting—Docetaxel—stomach cancer	6.84e-05	0.000722	CcSEcCtD
Crizotinib—Dyspepsia—Methotrexate—stomach cancer	6.83e-05	0.00072	CcSEcCtD
Crizotinib—Rash—Docetaxel—stomach cancer	6.79e-05	0.000716	CcSEcCtD
Crizotinib—Dermatitis—Docetaxel—stomach cancer	6.78e-05	0.000715	CcSEcCtD
Crizotinib—Decreased appetite—Methotrexate—stomach cancer	6.74e-05	0.000711	CcSEcCtD
Crizotinib—Oedema—Doxorubicin—stomach cancer	6.72e-05	0.000708	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Methotrexate—stomach cancer	6.7e-05	0.000706	CcSEcCtD
Crizotinib—Fatigue—Methotrexate—stomach cancer	6.69e-05	0.000705	CcSEcCtD
Crizotinib—Infection—Doxorubicin—stomach cancer	6.67e-05	0.000704	CcSEcCtD
Crizotinib—Vomiting—Capecitabine—stomach cancer	6.63e-05	0.000699	CcSEcCtD
Crizotinib—Shock—Doxorubicin—stomach cancer	6.61e-05	0.000697	CcSEcCtD
Crizotinib—Nervous system disorder—Doxorubicin—stomach cancer	6.59e-05	0.000695	CcSEcCtD
Crizotinib—Rash—Capecitabine—stomach cancer	6.57e-05	0.000693	CcSEcCtD
Crizotinib—Dermatitis—Capecitabine—stomach cancer	6.56e-05	0.000692	CcSEcCtD
Crizotinib—Skin disorder—Doxorubicin—stomach cancer	6.52e-05	0.000688	CcSEcCtD
Crizotinib—Paraesthesia—Epirubicin—stomach cancer	6.52e-05	0.000687	CcSEcCtD
Crizotinib—PLK4—Idarubicin—Doxorubicin—stomach cancer	6.5e-05	0.0174	CbGdCrCtD
Crizotinib—PLK4—Epirubicin—Doxorubicin—stomach cancer	6.5e-05	0.0174	CbGdCrCtD
Crizotinib—CYP3A5—endocrine gland—stomach cancer	6.49e-05	0.00061	CbGeAlD
Crizotinib—Dyspnoea—Epirubicin—stomach cancer	6.47e-05	0.000682	CcSEcCtD
Crizotinib—Nausea—Docetaxel—stomach cancer	6.39e-05	0.000674	CcSEcCtD
Crizotinib—Dyspepsia—Epirubicin—stomach cancer	6.39e-05	0.000674	CcSEcCtD
Crizotinib—Decreased appetite—Epirubicin—stomach cancer	6.31e-05	0.000665	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Epirubicin—stomach cancer	6.27e-05	0.000661	CcSEcCtD
Crizotinib—Fatigue—Epirubicin—stomach cancer	6.26e-05	0.00066	CcSEcCtD
Crizotinib—Constipation—Epirubicin—stomach cancer	6.21e-05	0.000655	CcSEcCtD
Crizotinib—Nausea—Capecitabine—stomach cancer	6.19e-05	0.000653	CcSEcCtD
Crizotinib—Body temperature increased—Methotrexate—stomach cancer	6.13e-05	0.000647	CcSEcCtD
Crizotinib—Paraesthesia—Doxorubicin—stomach cancer	6.03e-05	0.000636	CcSEcCtD
Crizotinib—ABCB1—hematopoietic system—stomach cancer	6e-05	0.000564	CbGeAlD
Crizotinib—Dyspnoea—Doxorubicin—stomach cancer	5.99e-05	0.000631	CcSEcCtD
Crizotinib—Dyspepsia—Doxorubicin—stomach cancer	5.91e-05	0.000623	CcSEcCtD
Crizotinib—ABL1—Daunorubicin—Epirubicin—stomach cancer	5.91e-05	0.0158	CbGdCrCtD
Crizotinib—ABL1—Doxorubicin—Epirubicin—stomach cancer	5.91e-05	0.0158	CbGdCrCtD
Crizotinib—ABL1—Idarubicin—Epirubicin—stomach cancer	5.91e-05	0.0158	CbGdCrCtD
Crizotinib—CYP3A4—digestive system—stomach cancer	5.89e-05	0.000554	CbGeAlD
Crizotinib—CYP3A5—liver—stomach cancer	5.85e-05	0.00055	CbGeAlD
Crizotinib—Decreased appetite—Doxorubicin—stomach cancer	5.84e-05	0.000616	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Doxorubicin—stomach cancer	5.8e-05	0.000611	CcSEcCtD
Crizotinib—Fatigue—Doxorubicin—stomach cancer	5.79e-05	0.000611	CcSEcCtD
Crizotinib—Constipation—Doxorubicin—stomach cancer	5.74e-05	0.000606	CcSEcCtD
Crizotinib—Body temperature increased—Epirubicin—stomach cancer	5.74e-05	0.000605	CcSEcCtD
Crizotinib—Asthenia—Methotrexate—stomach cancer	5.57e-05	0.000587	CcSEcCtD
Crizotinib—AURKA—Daunorubicin—Epirubicin—stomach cancer	5.5e-05	0.0147	CbGdCrCtD
Crizotinib—AURKA—Doxorubicin—Epirubicin—stomach cancer	5.5e-05	0.0147	CbGdCrCtD
Crizotinib—AURKA—Idarubicin—Epirubicin—stomach cancer	5.5e-05	0.0147	CbGdCrCtD
Crizotinib—ABCB1—epithelium—stomach cancer	5.48e-05	0.000516	CbGeAlD
Crizotinib—ABL1—Idarubicin—Doxorubicin—stomach cancer	5.47e-05	0.0146	CbGdCrCtD
Crizotinib—ABL1—Epirubicin—Doxorubicin—stomach cancer	5.47e-05	0.0146	CbGdCrCtD
Crizotinib—ABL1—Daunorubicin—Doxorubicin—stomach cancer	5.47e-05	0.0146	CbGdCrCtD
Crizotinib—Body temperature increased—Doxorubicin—stomach cancer	5.31e-05	0.00056	CcSEcCtD
Crizotinib—Diarrhoea—Methotrexate—stomach cancer	5.31e-05	0.00056	CcSEcCtD
Crizotinib—Asthenia—Epirubicin—stomach cancer	5.21e-05	0.000549	CcSEcCtD
Crizotinib—Dizziness—Methotrexate—stomach cancer	5.13e-05	0.000541	CcSEcCtD
Crizotinib—AURKA—Daunorubicin—Doxorubicin—stomach cancer	5.09e-05	0.0136	CbGdCrCtD
Crizotinib—AURKA—Idarubicin—Doxorubicin—stomach cancer	5.09e-05	0.0136	CbGdCrCtD
Crizotinib—AURKA—Epirubicin—Doxorubicin—stomach cancer	5.09e-05	0.0136	CbGdCrCtD
Crizotinib—Diarrhoea—Epirubicin—stomach cancer	4.97e-05	0.000524	CcSEcCtD
Crizotinib—Vomiting—Methotrexate—stomach cancer	4.93e-05	0.00052	CcSEcCtD
Crizotinib—Rash—Methotrexate—stomach cancer	4.89e-05	0.000516	CcSEcCtD
Crizotinib—Dermatitis—Methotrexate—stomach cancer	4.89e-05	0.000515	CcSEcCtD
Crizotinib—ABCB1—pancreas—stomach cancer	4.88e-05	0.00046	CbGeAlD
Crizotinib—CYP3A4—endocrine gland—stomach cancer	4.87e-05	0.000458	CbGeAlD
Crizotinib—Asthenia—Doxorubicin—stomach cancer	4.82e-05	0.000508	CcSEcCtD
Crizotinib—Dizziness—Epirubicin—stomach cancer	4.8e-05	0.000506	CcSEcCtD
Crizotinib—Vomiting—Epirubicin—stomach cancer	4.62e-05	0.000487	CcSEcCtD
Crizotinib—Nausea—Methotrexate—stomach cancer	4.61e-05	0.000486	CcSEcCtD
Crizotinib—Diarrhoea—Doxorubicin—stomach cancer	4.6e-05	0.000485	CcSEcCtD
Crizotinib—Rash—Epirubicin—stomach cancer	4.58e-05	0.000483	CcSEcCtD
Crizotinib—Dermatitis—Epirubicin—stomach cancer	4.57e-05	0.000482	CcSEcCtD
Crizotinib—Dizziness—Doxorubicin—stomach cancer	4.44e-05	0.000468	CcSEcCtD
Crizotinib—CYP3A4—liver—stomach cancer	4.39e-05	0.000413	CbGeAlD
Crizotinib—Nausea—Epirubicin—stomach cancer	4.31e-05	0.000455	CcSEcCtD
Crizotinib—Vomiting—Doxorubicin—stomach cancer	4.27e-05	0.00045	CcSEcCtD
Crizotinib—Rash—Doxorubicin—stomach cancer	4.24e-05	0.000447	CcSEcCtD
Crizotinib—Dermatitis—Doxorubicin—stomach cancer	4.23e-05	0.000446	CcSEcCtD
Crizotinib—ABCB1—lymphoid tissue—stomach cancer	4.22e-05	0.000397	CbGeAlD
Crizotinib—ABCB1—digestive system—stomach cancer	4.17e-05	0.000392	CbGeAlD
Crizotinib—Nausea—Doxorubicin—stomach cancer	3.99e-05	0.000421	CcSEcCtD
Crizotinib—ABCB1—bone marrow—stomach cancer	3.84e-05	0.000362	CbGeAlD
Crizotinib—ABCB1—endocrine gland—stomach cancer	3.45e-05	0.000324	CbGeAlD
Crizotinib—ABCB1—liver—stomach cancer	3.11e-05	0.000292	CbGeAlD
Crizotinib—ABCB1—lymph node—stomach cancer	2.38e-05	0.000224	CbGeAlD
Crizotinib—RIPK2—Signaling Pathways—TP53—stomach cancer	6.18e-07	3.32e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—KRAS—stomach cancer	6.18e-07	3.32e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—MAPK1—stomach cancer	6.15e-07	3.3e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—EGFR—stomach cancer	6.15e-07	3.3e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NOS3—stomach cancer	6.13e-07	3.29e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—CDKN1A—stomach cancer	6.13e-07	3.29e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—ERBB2—stomach cancer	6.13e-07	3.29e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—stomach cancer	6.09e-07	3.27e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MAPK3—stomach cancer	6.07e-07	3.26e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ALOX5—stomach cancer	6.06e-07	3.26e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—JUN—stomach cancer	6.06e-07	3.25e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PPP2R1A—stomach cancer	6.05e-07	3.25e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—PIK3CA—stomach cancer	6.02e-07	3.23e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—HRAS—stomach cancer	6.01e-07	3.23e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6R—stomach cancer	6e-07	3.22e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—VEGFA—stomach cancer	6e-07	3.22e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MAPK3—stomach cancer	5.99e-07	3.21e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PRKCB—stomach cancer	5.98e-07	3.21e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—DPYD—stomach cancer	5.97e-07	3.2e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—MAPK3—stomach cancer	5.96e-07	3.2e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6ST—stomach cancer	5.96e-07	3.2e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—STAT3—stomach cancer	5.94e-07	3.19e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GSTP1—stomach cancer	5.94e-07	3.19e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—STAT3—stomach cancer	5.92e-07	3.18e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—HRAS—stomach cancer	5.91e-07	3.17e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MYC—stomach cancer	5.9e-07	3.17e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CAV1—stomach cancer	5.89e-07	3.16e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—APOA1—stomach cancer	5.88e-07	3.16e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CDKN1B—stomach cancer	5.88e-07	3.16e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—CDKN1A—stomach cancer	5.88e-07	3.15e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—HMOX1—stomach cancer	5.85e-07	3.14e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—PIK3CA—stomach cancer	5.84e-07	3.14e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—PIK3CA—stomach cancer	5.84e-07	3.13e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—stomach cancer	5.83e-07	3.13e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—VEGFA—stomach cancer	5.83e-07	3.13e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—HRAS—stomach cancer	5.82e-07	3.13e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MYC—stomach cancer	5.82e-07	3.13e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CXCL8—stomach cancer	5.81e-07	3.12e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—KRAS—stomach cancer	5.81e-07	3.12e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—MYC—stomach cancer	5.8e-07	3.11e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MAPK1—stomach cancer	5.78e-07	3.1e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EGFR—stomach cancer	5.77e-07	3.1e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—STAT3—stomach cancer	5.77e-07	3.1e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—IL6—stomach cancer	5.75e-07	3.09e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—MAPK8—stomach cancer	5.74e-07	3.08e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ERBB2—stomach cancer	5.73e-07	3.08e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—APC—stomach cancer	5.72e-07	3.07e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—PIK3CA—stomach cancer	5.7e-07	3.06e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MAPK1—stomach cancer	5.7e-07	3.06e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EGFR—stomach cancer	5.69e-07	3.06e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MAPK3—stomach cancer	5.68e-07	3.05e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—MAPK1—stomach cancer	5.68e-07	3.05e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—EGFR—stomach cancer	5.67e-07	3.05e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—PIK3CA—stomach cancer	5.67e-07	3.05e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CDKN1B—stomach cancer	5.67e-07	3.05e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—MAPK3—stomach cancer	5.66e-07	3.04e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL6—stomach cancer	5.66e-07	3.04e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—stomach cancer	5.65e-07	3.03e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SERPINE1—stomach cancer	5.62e-07	3.02e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL6—stomach cancer	5.57e-07	2.99e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—HRAS—stomach cancer	5.57e-07	2.99e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MYC—stomach cancer	5.52e-07	2.96e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—TYMS—stomach cancer	5.52e-07	2.96e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MAPK3—stomach cancer	5.51e-07	2.96e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—STAT3—stomach cancer	5.47e-07	2.94e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GSTM1—stomach cancer	5.45e-07	2.93e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—KRAS—stomach cancer	5.45e-07	2.93e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CXCL8—stomach cancer	5.44e-07	2.92e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CDKN1A—stomach cancer	5.43e-07	2.91e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—RHOA—stomach cancer	5.42e-07	2.91e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCND1—stomach cancer	5.41e-07	2.91e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—HRAS—stomach cancer	5.4e-07	2.9e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MAPK1—stomach cancer	5.4e-07	2.9e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—HRAS—stomach cancer	5.4e-07	2.9e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EGFR—stomach cancer	5.4e-07	2.9e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—JUN—stomach cancer	5.4e-07	2.9e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—MAPK1—stomach cancer	5.38e-07	2.89e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—EGFR—stomach cancer	5.38e-07	2.89e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—KRAS—stomach cancer	5.38e-07	2.89e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NOS3—stomach cancer	5.37e-07	2.88e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MYC—stomach cancer	5.36e-07	2.88e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—KRAS—stomach cancer	5.36e-07	2.88e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—PIK3CA—stomach cancer	5.33e-07	2.86e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL6—stomach cancer	5.33e-07	2.86e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6R—stomach cancer	5.32e-07	2.85e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDKN1B—stomach cancer	5.31e-07	2.85e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTT1—stomach cancer	5.28e-07	2.83e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—HRAS—stomach cancer	5.27e-07	2.83e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MMP9—stomach cancer	5.25e-07	2.82e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HRAS—stomach cancer	5.25e-07	2.82e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MAPK1—stomach cancer	5.24e-07	2.82e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—STAT3—stomach cancer	5.24e-07	2.81e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EGFR—stomach cancer	5.24e-07	2.81e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CDKN1A—stomach cancer	5.24e-07	2.81e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MAPK3—stomach cancer	5.22e-07	2.8e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP2A6—stomach cancer	5.22e-07	2.8e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PPARG—stomach cancer	5.18e-07	2.78e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL6—stomach cancer	5.17e-07	2.78e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL6—stomach cancer	5.17e-07	2.78e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ERCC2—stomach cancer	5.13e-07	2.75e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MAPK8—stomach cancer	5.11e-07	2.74e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—KRAS—stomach cancer	5.1e-07	2.74e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—KRAS—stomach cancer	5.09e-07	2.73e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MYC—stomach cancer	5.08e-07	2.73e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKR1C3—stomach cancer	5.07e-07	2.72e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCND1—stomach cancer	5.06e-07	2.72e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—JUN—stomach cancer	5.05e-07	2.71e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL6—stomach cancer	5.05e-07	2.71e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL6—stomach cancer	5.02e-07	2.7e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ERBB2—stomach cancer	5.02e-07	2.7e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—PIK3CA—stomach cancer	5.01e-07	2.69e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—MAPK3—stomach cancer	5.01e-07	2.69e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—SERPINE1—stomach cancer	4.98e-07	2.67e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MAPK1—stomach cancer	4.97e-07	2.67e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—EGFR—stomach cancer	4.97e-07	2.67e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—KRAS—stomach cancer	4.95e-07	2.66e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ENO1—stomach cancer	4.94e-07	2.65e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—PIK3CA—stomach cancer	4.94e-07	2.65e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HRAS—stomach cancer	4.93e-07	2.65e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—PIK3CA—stomach cancer	4.92e-07	2.64e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MMP9—stomach cancer	4.92e-07	2.64e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDKN1A—stomach cancer	4.9e-07	2.63e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—stomach cancer	4.85e-07	2.6e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—STAT3—stomach cancer	4.84e-07	2.6e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MTHFR—stomach cancer	4.82e-07	2.59e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—RHOA—stomach cancer	4.8e-07	2.58e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MAPK8—stomach cancer	4.78e-07	2.57e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—stomach cancer	4.78e-07	2.57e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—MAPK1—stomach cancer	4.77e-07	2.56e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—EGFR—stomach cancer	4.77e-07	2.56e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CXCL8—stomach cancer	4.76e-07	2.56e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NOS3—stomach cancer	4.75e-07	2.55e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL6—stomach cancer	4.72e-07	2.54e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—stomach cancer	4.72e-07	2.53e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—KRAS—stomach cancer	4.69e-07	2.52e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PIK3CA—stomach cancer	4.69e-07	2.52e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—PIK3CA—stomach cancer	4.67e-07	2.51e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—STAT3—stomach cancer	4.67e-07	2.51e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ALB—stomach cancer	4.66e-07	2.5e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN1B—stomach cancer	4.65e-07	2.5e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HRAS—stomach cancer	4.64e-07	2.49e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MAPK3—stomach cancer	4.62e-07	2.48e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HRAS—stomach cancer	4.57e-07	2.45e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—HRAS—stomach cancer	4.56e-07	2.45e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PIK3CA—stomach cancer	4.55e-07	2.44e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—stomach cancer	4.53e-07	2.43e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—KRAS—stomach cancer	4.5e-07	2.42e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MYC—stomach cancer	4.5e-07	2.41e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MAPK3—stomach cancer	4.46e-07	2.4e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—NOS3—stomach cancer	4.46e-07	2.39e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CAV1—stomach cancer	4.45e-07	2.39e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ERBB2—stomach cancer	4.44e-07	2.39e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL6—stomach cancer	4.44e-07	2.38e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—APOA1—stomach cancer	4.44e-07	2.38e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCND1—stomach cancer	4.44e-07	2.38e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—JUN—stomach cancer	4.43e-07	2.38e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—stomach cancer	4.42e-07	2.37e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—stomach cancer	4.4e-07	2.36e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MAPK1—stomach cancer	4.4e-07	2.36e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—EGFR—stomach cancer	4.4e-07	2.36e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CD44—stomach cancer	4.38e-07	2.35e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL6—stomach cancer	4.38e-07	2.35e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—STAT3—stomach cancer	4.37e-07	2.35e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—IL6—stomach cancer	4.36e-07	2.34e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MYC—stomach cancer	4.34e-07	2.33e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HRAS—stomach cancer	4.34e-07	2.33e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—HRAS—stomach cancer	4.32e-07	2.32e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PIK3CA—stomach cancer	4.31e-07	2.32e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MMP9—stomach cancer	4.31e-07	2.31e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN1A—stomach cancer	4.29e-07	2.3e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MAPK1—stomach cancer	4.25e-07	2.28e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EGFR—stomach cancer	4.25e-07	2.28e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CXCL8—stomach cancer	4.22e-07	2.26e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HRAS—stomach cancer	4.21e-07	2.26e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MAPK8—stomach cancer	4.19e-07	2.25e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MAPK3—stomach cancer	4.18e-07	2.24e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—KRAS—stomach cancer	4.16e-07	2.23e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL6—stomach cancer	4.15e-07	2.23e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL6—stomach cancer	4.14e-07	2.22e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—PIK3CA—stomach cancer	4.14e-07	2.22e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN1B—stomach cancer	4.12e-07	2.21e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTGS2—stomach cancer	4.08e-07	2.19e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MYC—stomach cancer	4.06e-07	2.18e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL6—stomach cancer	4.03e-07	2.16e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KRAS—stomach cancer	4.01e-07	2.15e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—HRAS—stomach cancer	3.99e-07	2.14e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MAPK1—stomach cancer	3.97e-07	2.13e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EGFR—stomach cancer	3.97e-07	2.13e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCND1—stomach cancer	3.93e-07	2.11e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—JUN—stomach cancer	3.92e-07	2.1e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PPARG—stomach cancer	3.91e-07	2.1e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—stomach cancer	3.87e-07	2.08e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—STAT3—stomach cancer	3.83e-07	2.06e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—HRAS—stomach cancer	3.83e-07	2.05e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6—stomach cancer	3.82e-07	2.05e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PIK3CA—stomach cancer	3.82e-07	2.05e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MMP9—stomach cancer	3.81e-07	2.05e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN1A—stomach cancer	3.8e-07	2.04e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KRAS—stomach cancer	3.75e-07	2.02e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PPP2R1A—stomach cancer	3.73e-07	2e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAPK8—stomach cancer	3.71e-07	1.99e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PIK3CA—stomach cancer	3.69e-07	1.98e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6—stomach cancer	3.66e-07	1.97e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MAPK3—stomach cancer	3.66e-07	1.96e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTP1—stomach cancer	3.66e-07	1.96e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HMOX1—stomach cancer	3.61e-07	1.94e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—stomach cancer	3.56e-07	1.91e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MYC—stomach cancer	3.56e-07	1.91e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—HRAS—stomach cancer	3.53e-07	1.9e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ALB—stomach cancer	3.52e-07	1.89e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MAPK1—stomach cancer	3.48e-07	1.87e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EGFR—stomach cancer	3.48e-07	1.87e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PIK3CA—stomach cancer	3.45e-07	1.85e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—stomach cancer	3.42e-07	1.84e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HRAS—stomach cancer	3.41e-07	1.83e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TYMS—stomach cancer	3.4e-07	1.83e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—STAT3—stomach cancer	3.39e-07	1.82e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6—stomach cancer	3.38e-07	1.82e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NOS3—stomach cancer	3.36e-07	1.81e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTM1—stomach cancer	3.36e-07	1.8e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—stomach cancer	3.34e-07	1.79e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KRAS—stomach cancer	3.29e-07	1.76e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6—stomach cancer	3.26e-07	1.75e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAPK3—stomach cancer	3.24e-07	1.74e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HRAS—stomach cancer	3.19e-07	1.71e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ERCC2—stomach cancer	3.16e-07	1.7e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MYC—stomach cancer	3.15e-07	1.69e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAPK1—stomach cancer	3.08e-07	1.65e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EGFR—stomach cancer	3.08e-07	1.65e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTGS2—stomach cancer	3.08e-07	1.65e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6—stomach cancer	3.05e-07	1.64e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CA—stomach cancer	3.02e-07	1.62e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MTHFR—stomach cancer	2.97e-07	1.59e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—stomach cancer	2.92e-07	1.57e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KRAS—stomach cancer	2.91e-07	1.56e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HRAS—stomach cancer	2.79e-07	1.5e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CAV1—stomach cancer	2.74e-07	1.47e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—APOA1—stomach cancer	2.73e-07	1.47e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6—stomach cancer	2.67e-07	1.44e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CA—stomach cancer	2.67e-07	1.44e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—stomach cancer	2.59e-07	1.39e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CA—stomach cancer	2.51e-07	1.35e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HRAS—stomach cancer	2.47e-07	1.33e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PPARG—stomach cancer	2.41e-07	1.29e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6—stomach cancer	2.37e-07	1.27e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ALB—stomach cancer	2.17e-07	1.16e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NOS3—stomach cancer	2.07e-07	1.11e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS2—stomach cancer	1.89e-07	1.02e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CA—stomach cancer	1.89e-07	1.02e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CA—stomach cancer	1.17e-07	6.26e-07	CbGpPWpGaD
